News and Updates

Explore Medicines360’s latest news and resources

Press Releases

Medicines360, WCG, and Population Services International Announce Launch of AVIBELA™ Hormonal Intrauterine System in Madagascar

Approval Expands Contraceptive Access for Women in Madagascar SAN FRANCISCO and SAN DIEGO and WASHINGTON – Medicines360, WCG, and Population Services International (PSI) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Madagascar. This is the first registration and launch of Medicines360’s hormonal intrauterine system (IUS or IUD) in Africa. Copyright Evelyn Hockstein/Medicines360 AVIBELA’s introduction in Madagascar is supported by WCG’s […]

Read More >
Press Releases

Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented five-year data from their ongoing multi-center U.S.-based […]

Read More >
Press Releases

FDA Acceptance of Medicines360’s Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Application Seeks to Extend Duration of Use Up to 5 Years for LILETTA DUBLIN and SAN FRANCISCO – Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360’s […]

Read More >
Press Releases

Study Finds Z-CAN Program, Supported by Medicines360, Increased Use of LARCs by Women in Puerto Rico During Zika Outbreak

Access to Full Range of Contraception, Plus Patient-Centered Counseling, Successful Formula for Woman-led Prevention of Unintended Pregnancy SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health. The report examined the effectiveness of the CDC […]

Read More >
Press Releases

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years

Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN and SAN FRANCISCO – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use […]

Read More >
Press Releases

Medicines360 and Allergan Present Four-Year Multi-Center Pivotal Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at the 2017 ACOG Meeting

Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, presented four-year data from their ongoing multi-center U.S.-based pivotal trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at the American College of Obstetricians and Gynecologists (ACOG) annual clinical and scientific meeting.

Read More >

FEATURED UPDATES

Press Releases

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Four Years

Approval Offers Women Additional Flexibility for Pregnancy Prevention DUBLIN and SAN FRANCISCO – Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use […]

Read More >